Order Trans-D

 Just the Facts - TransD

 By: Rashid A. Buttar- DO FAAPM, FACAM, FAAIM

All three studies that we did on TransD showed similar  results and other doctors have since reproduced the same findings in their own patient populations all over the world. Details of all three studies are available online. The largest of these was a multicentered, double-blind, placebo-controlled, crossover study initiated in twenty-five locations throughout the United States. Two groups, totaling 117 patients, were monitored over an eight-week period, and then the control group (on placebo) was crossed over into the experimental group (on TransD) for another eight weeks.

At the time of initiating TransD, there was a 462 percent increase in endogenous (what your own body produces) hGH levels just ninety minutes after the first application in the group on TransD. By the end of the second week, the TransD group showed that endogenous hGH had increased to 815 percent from what was measured at baseline to ninety minutes after application. By the fifth week, the TransD group showed there was a phenomenal 1,754 percent increase in endogenous hGH from what was measured at baseline to ninety minutes after application. Remember, this is without giving any end hormones and all achieved while respecting the normal, healthy NIFBL.

All hGH levels were assessed by both radioimmunoassay and chemiluminescent immunoassay testing in all 117 patients.

Other laboratory findings measured during the same period of time included insulin, cortisol and IGF-1 levels, all of which consistently decreased, with all the participating patients reporting subjective improvements in various areas. At the eighth week on TransD, however, we observed an interesting phenomenon, which we didn’t anticipate. We actually observed an unexpected drop in the endogenous hGH levels, down to 609 percent (from a high of 1,754 percent) over baseline. We were at a loss to explain this initially.

After looking at the results a bit closer, it became clear there were two very distinct possibilities to explain why the hGH levels had dropped by the eighth week. During the fifth week, there was a tremendous increase in endogenous hGH by 1,754 percent. This means the amount of hGH released by the pituitary was, on average, seventeen and a half times more than normally released! So if we’re getting such a huge increase in hGH, do you think it’s possible that we were exceeding the physiological limits? Absolutely!

However, our safety mechanism was completely functional and intact, so the NIFBL kicked in. This is the first of the two possibilities explaining the drop in endogenous hGH levels. The hypothalamus registered “too much hGH” and the NIFBL went into action, initiated by somatostatin, which relays the message to the pituitary to take a break and stop releasing hGH.

No matter how much TransD we continue to take or how many signals reach the pituitary as a result, the NIFBL is in control and no hGH will be released. Until the hypothalamus registers the levels of hGH have come back down and stops sending somatostatin (which tells the pituitary to hold back), no more hGH can be released. The beauty here is that it’s impossible to be out of balance!

The second possibility for the drop of hGH during the eighth week was that the pituitary gland couldn’t keep up with the demand to produce so much more hGH than what it was normally used to producing. Remember, the pituitary gland stores hGH and releases it in a pulsatile manner. But due to the effectiveness of TransD causing a greater than seventeen-fold increase in hGH to be released, the pituitary reserves may have become depleted and additional time was required for the hGH to be replenished.

Regardless of whether it was the NIFBL or simply a depletion issue, hGH levels went from a high of 1,754 percent down to 609 percent by week eight. Study patients were instructed to take two weeks off at the conclusion of the eight-week study, and TransD was then resumed after those two weeks. Findings revealed that the same improvement had recurred, with hGH increasing and IGF-1 decreasing as had previously been observed before the two-week break. About 20 percent to 25 percent of the patients from both groups were followed intermittently over the following two years, and all subjects reported significant and consistent improvements while continuing to use TransD. There was no evidence of a buildup or of resistance to TransD reported by any of the study groups that we followed.

Taking a one- to two-week break from TransD every eight weeks appeared to reset the hypothalamic-pituitary axis, and the peaks in hGH levels resumed immediately. In fact, I’ve been on TransD since 1998, and I can still tell the difference between the way I feel when I’m taking it and when I’ve been off it for a week or two. For me, the effect is highly discernible. %uestions may arise regarding what, exactly, the optimum hGH levels are, but the answer actually varies from individual to individual because it’s based upon biological individuality and genetic uniqueness.

Defining “optimum hGH levels” also should not be confused with diagnostic versus therapeutic efficacy, that is, the 5 ng/dl levels typically discussed by endocrinologists who are doing dopamine challenge tests for diagnostic purposes to establish hGH deficiency. The point is TransD provides what each individual needs almost in a personalized manner. The results and benefits people report using TransD extend throughout the complete physiological gamut, indicating that optimization of the entire system is taking place.

The most common benefits reported are discussed on next page

Turning Back Time >>>>>>>>>>>>>>>>>>>>>>>>>>>>>Next...

<< Previous    [1]  2    Next >>